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Abstract
Objective:  Clinical  and  immunological  data  about  HIV  in  older  adults  from  low  and  middle  income  countries  is
scarce. We aimed to describe differences between younger and older adults with HIV starting antiretroviral therapy in
two low–income African countries.
Methods: Setting: HIV clinics in Uganda and Zimbabwe. Design: Secondary exploratory cross-sectional analysis of
the DART randomized controlled trial. Outcome Measures: Clinical and laboratory characteristics were compared
between  adults  aged  18-49  years  (younger)  and  ≥  50  years  (older),  using  two  exploratory  multivariable  logistic
regression models, one with HIV viral load (measured in a subset pre-ART) and one without.
Results: A total of 3316 eligible participants enrolled in DART were available for analysis; 219 (7%) were ≥ 50 years
and 1160 (35%) were male. Across the two adjusted regression models, older adults had significantly higher systolic
blood pressure, lower creatinine clearance and were consistently less likely to be females compared to younger
adults with HIV. Paradoxically, the models separately suggested that older adults had statistically significant (but not
clinically important) higher CD4+ cell counts and higher plasma HIV–1 viral copies at initiation. Crude associations
between older age and higher baseline hemoglobin, body mass index, diastolic blood pressure and lower WHO
clinical stage were not sustained in the adjusted analysis.
Conclusions: Our study found clinical and immunological differences between younger and older adults, in a cohort
of Africans starting antiretroviral therapy. Further investigations should explore how these differences could be used
to ensure equity in service delivery and affect outcomes of antiretroviral therapy.
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Globally, the proportion of older adults is increasing [1]. In
regard  to  HIV,  persons  50  years  and  above  are  considered
“older adults” [2–4]. In this fourth decade of the AIDS epidemic,
the HIV–infected population is growing older primarily due to
successful antiretroviral therapy (ART) but also among those
newly diagnosed [5]. Reports from high-income countries show
that  adults  over  50  years  doubled  from  10-15%  of  the  HIV–
infected population in 2005, to about 30% by 2010 [6,7]. This
phenomenon has also been observed in sub–Saharan Africa
[8].
Older  adults  with  HIV  present  with  different  clinical,
immunological  and  even  social  profiles  which  potentially
influence outcomes [9–14]. For example, adults aging with HIV
experience  multiple  co-morbidities  with  resultant  poly-
pharmacy, may respond differently to ART, and are commonly
stigmatized or socially isolated. However, existing evidence on
aging and HIV/AIDS is largely from high income countries. The
few  publications  from  sub–Saharan  Africa  do  not  provide  as
much information regarding some of the co-morbidities such as
Hepatitis B and C co-infection, renal dysfunction, hypertension
or viral loads [8,15–17]. In order to explore these issues of HIV
patients  initiating  ART,  we  compared  clinical  and
immunological  differences  between  older  (≥  50  years)  and
younger  (18-49  years)  adults  starting  ART  in  Uganda  and
Zimbabwe  which  are  low  income  countries  in  sub–Saharan
Africa.
Methods
Study design, procedures and setting
In  this  secondary  data  analysis,  we  used  information  from
the Development of Anti-Retroviral Therapy in Africa (DART)
trial.  DART  was  an  open  randomized  trial  comparing  two
management strategies for monitoring ART, and details of the
methods  have  been  reported  elsewhere  [18].  Briefly,  3316
eligible  symptomatic  (WHO  stage  2–4)  HIV–infected  adults
(≥18  years)  with  CD4+  counts  less  than  200  cells/ml  who
reported  no  previous  ART  apart  from  to  prevent  mother–to–
child transmission, were enrolled from three centres in Uganda
and  one  centre  in  Zimbabwe  from  15  January  2003  to  28
October  2004.  Viral  loads  (n=968  at  baseline)  were  done
retrospectively  using  stored  samples,  and  were  not  used  for
clinical management.
Statistical analysis
We conducted this exploratory analysis to identify variables
that differed significantly between the younger and older adults
with HIV (18-49 versus >50 years) at enrollment into ART care.
We summarized clinical measures (sex, systolic and diastolic
blood  pressure,  body  mass  index,  WHO  clinical  stage),
laboratory  results  (hemoglobin,  CD4+  cell  counts,  viral  load,
creatinine,  alanine  and  aspartate  amino–transferase),
infectious (hepatitis B surface antigen and anti-hepatitis C) and
non-communicable (hypertension, overweight and obesity) co-
morbidities  using  frequencies,  percentages  and  measures  of
central tendency as appropriate. We referred to World Health
Organization cut offs for hypertension, overweight and obesity.
We computed creatinine clearance using the Cockcroft–Gault
equation  [19].  We  then  explored  associations  between  age
(18-49  versus  >50  years)  and  each  variable  using  logistic
regression. Tests were two–sided and considered significant if
P<0.05.  Variables  with  P<0.2  in  univariate  analysis  were
included in a multivariable logistic regression model to estimate
the  adjusted  Odds  Ratios  (aOR)  and  their  95%  confidence
intervals  (95%  CI).  We  excluded  creatinine  and  body  mass
index  (BMI)  from  adjusted  analyses  due  to  their  significant
correlation  with  creatinine  clearance  (r2  =-0.6  and  r2=0.33,
respectively, both p<0.0001). Because not all participants had
HIV-1  RNA  measures  taken,  we  employed  two  adjusted
regression models. Model 1 incorporated all variables eligible
for inclusion from the univariate analysis (P<0.2), except viral
load,  creatinine  and  BMI  (as  above).  An  interaction  term
between sex and hemoglobin was included since a previous
analysis  showed  that  women  had  significantly  lower
hemoglobin  in  DART  [20].  Model  2  included  viral  load
measurements into model 1 in the subgroup of participants with
pre-ART HIV-1 RNA levels available.
Ethical considerations
The  DART  trial  was  approved  by  ethics  committees  in
Uganda,  Zimbabwe  and  United  Kingdom.  This  secondary
analysis was approved by the Joint Clinical Research Centre
Institutional Review Board in Uganda. Written informed consent
was  obtained  from  each  enrolled  participant  for  trial
participation and provision and analysis of data.
Results
Baseline characteristics
3316  eligible  participants  were  included  in  the  DART  trial.
Overall, the majority were females (65%) and the mean age
(SD) was 37.6 years (7.8) with 219 (7.0%) of the participants
aged ≥ 50 years or older. Only 968 (29.2%) participants had
baseline viral loads measured and the mean (SD) was 5.4 (0.7)
log 10 copies/mL. Further details are in table 1.
Prevalence of co-morbidities
The  prevalence  of  systolic  and  diastolic  hypertension  was
21.3%  and  19.0%  for  older  adults;  and  9.2%  and  3.5%  for
younger adults with HIV (both, p<0.001) respectively. 24.0% of
older adults and 14.8% younger adults were either overweight
or  obese  (p<0.001).  The  prevalence  of  anti-hepatitis  C  virus
sero-positivity was 3.7% and 2.3% for older and younger adults
respectively (p=0.17); whilst that for hepatitis B surface antigen
was  5.6%  and  9.6%  respectively  (p=0.05).  Finally,  the
proportion of having at least two co-morbidities (communicable
and or non-communicable) was 11.4% and 5.1% among older
and younger adults respectively (p<0.001) (Data not tabulated).
Differences between older (≥50 years) and younger
(18-49 years) adults with HIV and AIDS
In  the  adjusted  analysis  without  viral  load  data  (table  2,
model 1), there were significantly fewer females among older
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had  significantly  higher  systolic  blood  pressure  (aOR:  1.05,
95% CI: 1.03-1.06, p<0.001), higher CD4+ cell counts (aOR:
1.00,  95%  CI:  1.00-1.01,  p=0.009)  and  lower  creatinine
clearance  (OR:  0.97,  95%  CI:  0.96-0.97,  p<0.001).  The
association  between  higher  hemoglobin  and  older  age
remained  significant  among  females,  sustaining  the  effect
modification even after adjustment (heterogeneity p=0.003).
Using  viral  load  in  the  sub-population  where  this  was
available (table 2, model 2) the association between older age
and  higher  systolic  blood  pressure  and  lower  creatinine
clearance  was  maintained  (p<0.001).  Additionally,  females
were significantly fewer in the older age group (p=0.025). The
effect modification of sex in the association between older age
and  higher  hemoglobin  among  females  also  remained
significant (heterogeneity p=0.049). However, higher viral load
(p=0.005) remained independently associated with older adults
infected with HIV instead of CD4+, which no longer provided
independent information (p=0.4).
Discussion
HIV and aging is an inevitable global health challenge today
[21]. The world population is aging to the extent that chronic
diseases are on the rise and stretching health care budgets,
particularly  in  sub–Saharan  Africa  [22].  Still,  in  low  income
countries like Uganda and Zimbabwe, the existing high burden
of  infectious  diseases  including  HIV/AIDS,  tuberculosis  and
malaria, presents a dual challenge to the health systems [22].
Therefore,  innovative  strategies  to  integrate  care  for  older
adults  are  urgently  needed  and  understanding  the
Table 1. Characteristics at ART initiation stratified by age < 50 years and age ≥ 50 years.
Variable N = 3316 18-50 years ≥ 50 years P-Value
n (%)   3097 (93) 219 (7)  
Age (years, mean, SD) 37.6 (7.8) 36.3 (6.3) 55.1 (4.4) P<0.001
Sex        
Male (%) 1160 (3,5) 1054 (90.9) 106 (9.1) P<0.001
Female (%) 2156 (65) 2043 (94.8) 113 (5.2)  
BMI        
mean (SD) 21.7 (3.8) 21.6 (3.8) 22.5 (3.9) P<0.001
Blood Pressure (mm Hg)        
Systolic, mean (SD) 110.6 (14.7) 109.9 (13.9) 120.9 (20.2) P<0.001
Diastolic, mean (SD) 72.3 (11.1) 71.9 (10.8) 77.9 (13.6) P<0.001
WHO Clinical Stage (%)        
II 673 (20) 620 (92) 53 (8) P=0.077
III 1864 (56) 1737 (93) 127 (7)  
IV 779 (24) 740 (95) 39 (5)  
CD4+ (cells/µL)        
median (IQR) 86 (81–139) 85 (30–138) 92 (45–147) P=0.222
Viral Load (log10 cp/mL)      
mean (SD) 5.4 (0.7) 5.4 (0.7) 5.7 (0.5) P=0.003
Hemoglobin (g/dL)        
mean (SD) 11.5 (1.7) 11.5 (1.8) 11.7 (1.5) P=0.078
Creatinine (mg/dL)        
mean (SD) 0.91 (0.27) 0.90 (0.27) 0.98 (0.26) P<0.001
ALT (mmol/L)        
median (IQR) 25 (18–36) 25 (18–36) 23 (17–33) P=0.008
AST (mmol/L)        
median (IQR) 34 (26–48) 34 (26–48) 34 (25–44) P=0.895
Hepatitis B virus        
pos (%) 302 (9.3) 290 (96) 12 (4) P=0.053
neg (%) 2,950 (90.7) 2,747 (93.1) 203 (6.9)  
Hepatitis C virus        
pos (%) 77 (2.4) 69 (89.6) 8 (10.4) P=0.177
neg (%) 3,176 (97.6) 2,969 (93.5) 207 (6.5)  
Abbreviations: ALT – Alanine transaminase; AST – Aspartate transaminase; BMI – Body Mass Index; CD4+ – Cluster of Differentiation; CI – Confidence Interval; cp –
copies; IQR – Inter Quartile Range; neg – negative; OR – Odds Ratio; pos – positive; SD – Standard Deviation; WHO – World Health Organization; dL – deciliter; g – grams;
Hg – mercury; mmol – millimols; mL − milliliter; mm – millimeters; µL – microliter
* n=968 (< 50 years n = 912; > 50 years n = 56).
doi: 10.1371/journal.pone.0076158.t001
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[3,23].
Our  study  explored  clinical  and  immunological  differences
associated  with  older  adults  with  HIV  and  AIDS  starting
antiretroviral therapy. Whilst such data are largely from the high
income  settings,  few  studies  from  sub–Saharan  Africa  have
reported laboratory biomarkers for adults with HIV and AIDS
older  than  50  years.  In  the  DART  cohort,  older  adults  had
significantly  higher  systolic  blood  pressure,  lower  creatinine
clearance, higher CD4+ cell counts, and higher plasma HIV–1
RNA  viral  copies/mL,  compared  to  younger  adults  in  the
multivariable  regression  models.  Women  were  also
proportionately  less  well  represented,  despite  making  up  the
majority of the trial population.
That  older  adult  females  were  significantly  fewer  in
Zimbabwe  and  Uganda  raises  concern  of  gender  inequity  in
accessing  HIV  and  AIDS  care  in  low  income  countries.  This
finding  is  corroborated  in  a  recent  study  by  Negin  and
colleagues who reported that older adults in Malawi were more
likely to be male [24]. Indeed, older adult females with HIV are
probably widowed, neglected and lack resources or the social
fabric  to  reach  HIV  care  and  treatment  services  [25].
Alternatively,  this  could  be  a  cohort  effect  depicting  earlier
mortality  among  females  with  HIV  and  AIDS  compared  to
males  such  that,  only  those  who  survived  accessed  care.
However,  given  results  from  a  recent  systematic  review  that
men have worse outcomes even on ART, and that majority of
trial  participants  were  women,  this  is  quite  unlikely  [26].
Noteworthy,  this  could  be  a  consequence  of  earlier  sexual
debut associated with riskier sexual behavior and probably HIV
infection  in  females  compared  to  males  [27,28].  On  the
contrary,  older  men  may  be  more  sexually  active  and  with
multiple partners, thus increasing their risk of HIV than older
women [29]. Possibly, the DART recruitment procedures and
avenues  could  have  systematically  excluded  older  women.
Regardless of the underlying reason, our findings highlight the
importance of HIV treatment and care interventions in Africa
mainstreaming  gender  issues  to  improve  access,  even  for
females  older  than  50  years  who  are  naturally  no  longer
reproductive. Notably, menopause leads to changes in immune
response,  vaginal  or  cervical  epithelium  and  secretions  that
may influence HIV transmission or progression among those
who remain sexually active [30–32]. Hence, such programmes
could  consider  expanding  their  maternal  and  child  health
paradigm to include women’s health. In relation to this, older
adult  females  had  consistently  higher  hemoglobin  levels
compared to the younger reproductive age group (potentially
due to child-bearing in the latter) which underscores the point
that their clinical needs are indeed different.
It  is  certainly  not  surprising  that  older  adults  had  higher
systolic blood pressure and lower creatinine clearance. Older
age  is  characterized  by  general  decline  in  organ  (renal)
function,  narrowing  and  hardening  of  blood  vessels  [33–35].
However, recent evidence from Europe and America suggests
that there is an excess risk of morbidity and mortality due to
cardiovascular  and  renal  diseases  among  HIV–infected
Table 2. Logistic regression model for characteristics at ART initiation for adults who were older (≥ 50 years) compared to
younger ones (18-50 years) (N=3316).
Variable Unadjusted §Adjusted Model 1 (n=3184) Ω Adjusted Model 2 (n=943)
  OR 95% CI p-value aOR 95% CI p-value aOR 95% CI p-value
Female 0.55 0.42-0.72 <0.001 0.03 0.00-0.19 <0.001 0.01 0.00-0.38 0.016
BMI (Kg/M2) 1.06 1.02-1.09 0.001 – – – – – –
Syst. BP (mm Hg) 1.04 1.03-1.05 <0.001 1.05 1.03-1.06 <0.001 1.06 1.03-1.09 <0.001
Diast. BP (mm Hg) 1.04 1.03-1.06 <0.001 0.99 0.98-1.02 0.728 1.00 0.96-1.03 0.597
α WHO stage 0.79 0.64-0.97 0.027 0.98 0.78-1.24 0.878 1.19 0.56-2.56 0.649
CD4+ (cells/µL) 1.00 1.00-1.01 0.009 1.00 1.00-1.01 0.034 1.00 1.00-1.01 0.359
*VL (log 10 cp/mL) 1.97 1.27-3.05 0.002 – – – 2.51 1.07-5.87 0.034
Hb (g/dL) 1.07 0.99-1.16 0.078 0.91 0.82-1.03 0.125 0.78 0.60-1.00 0.108
Female Hb (g/dL) 1.28 1.09-1.51 0.003 1.29 1.09-1.54 0.003 1.51 1.06-2.18 0.024
Cr (mg/dL). 2.19 1.48 - 1.26 <0.001 – – – – – –
Cr. clear (mL/min). 0.97 0.96-0.98 <0.001 0.97 0.96-0.97 <0.001 0.95 0.94-0.97 <0.001
ALT (mmol/L) 0.99 0.99-1.00 0.349 – – – – – –
AST (mmol/L) 0.99 0.99-1.00 0.243 – – – – – –
Hep. B sAg (pos) 0.56 0.31-1.01 0.056 0.60 0.32-1.11 0.101 0.28 0.04-2.20 0.225
Hep. C (pos) 1.66 0.79-3.50 0.181 1.52 0.67-3.36 0.302 1.54 0.25-6.86 0.602
Abbreviations: ALT – Alanine transaminase; AST – Aspartate transaminase; BMI – Body Mass Index; clear. – clearance; CD4+ – Cluster of Differentiation; CI – Confidence
Interval; cp – copies; Cr. – Creatinine; IQR – Inter Quartile Range; Kg – Kilogramme; M2 – Meter; SD – Standard Deviation; WHO – World Health Organization; dL –
deciliter; g – grams; Hg – mercury; mmol – millimols; mL − milliliter; mm – millimeters; µL – microliter
* n=968 (
< 50 years n = 912; > 50 years n = 56) in log 10 copies per milliliter.
§ Baseline adjusted model; Ω - model with viral load, interaction between gender and hemoglobin; and creatinine clearance (BMI excluded)
α − WHO stages 2, 3 & 4 included as a linear trend
doi: 10.1371/journal.pone.0076158.t002
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older  adults  infected  with  HIV  may  require  even  closer
monitoring of their renal and cardiovascular function, bearing in
mind resultant poly-pharmacy and excess burden to the organs
in the event of co-administration of treatment.
Although  older  adults  had  statistically  higher  CD4+  cell
counts  and  higher  plasma  HIV–1  RNA  levels  compared  to
younger adults, clinically this should be interpreted cautiously.
Coupled with the finding of fewer older adults in the lower WHO
stages  3  and  4  univariate  analysis,  the  higher  CD4  counts
suggests either earlier presentation and access to HIV care by
older adults, or that more older adults died before they could
access care, leaving those survivors who joined the DART trial
with better underlying prognosis. The higher viral loads in older
persons would tend to support the latter explanation, although
they could also reflect decreased ability of the older immune
system to respond to HIV [38].
This study had limitations, which can be addressed by future
research.  Relatively  few  older  adults  were  recruited  in  the
DART trial meaning power to detect differences between older
and younger adults was low. In addition viral load results were
available for only a third of the participants, thus limiting power
of  the  findings  in  the  second  model.  Certain  data  were  not
collected including substance abuse, mental health as well as
specific  biomarkers  such  as  cholesterol,  D–dimer,  cystatin  C
and IL–6 all of which have been found to predict HIV treatment
outcomes  among  older  adults  in  western  cohorts  [39,40].
Lastly, a control group of non–HIV infected individuals would
have provided vital information on the effect of HIV infection
itself. Nonetheless, this is among the first studies on HIV and
aging  to  explore  clinical  and  immunological  differences  in  a
sub–Saharan African cohort.
Conclusions
Our study explored and identified some bio-markers which
may be useful in optimizing monitoring of care for older adults
with  HIV  and  AIDS.  We  also  exposed  information  gaps  for
future  research  in  cohorts  of  older  adult  Africans  with  HIV.
These  include  establishing  non–HIV  infected  cohorts  to
compare whether indeed in this setting, there is an interaction
between  aging  and  HIV  in  the  clinical,  immunological
differences  identified  in  our  study;  and  which  of  these  are
optimal for reliably predicting outcomes of HIV treatment.
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